Last reviewed · How we verify
SFA002
At a glance
| Generic name | SFA002 |
|---|---|
| Sponsor | SFA Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients (PHASE2, PHASE3)
- Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SFA002 CI brief — competitive landscape report
- SFA002 updates RSS · CI watch RSS
- SFA Therapeutics portfolio CI